✦ LIBER ✦

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

✍ Scribed by Abouharb, S.; Litton, J.K.

Book ID: 123264793
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 56 KB
Volume: 23
Category: Article
ISSN: 1043-321X
DOI: 10.1016/j.breastdis.2012.03.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictors of contralateral breast cance

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

✍ Metcalfe, K; Gershman, S; Lynch, H T; Ghadirian, P; Tung, N; Kim-Sing, C; Olopad 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 345 KB

Risks of contralateral breast cancer in

Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

✍ Munaza Ahmed; A. Howell; F. Lalloo; G. Evans 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Tamoxifen and Risk of Contralateral Brea

Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

✍ Phillips, K.-A.; Milne, R. L.; Rookus, M. A.; Daly, M. B.; Antoniou, A. C.; Peoc 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 142 KB

The risk of primary and contralateral br

The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1 / BRCA2 mutation carriers

✍ Vencken, Peggy M. L. H.; Kriege, Mieke; Hooning, Maartje; Menke-Pluymers, Marian 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB

Risk reduction of contralateral breast c

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers

✍ van Sprundel, T C; Schmidt, M K; Rookus, M A; Brohet, R; van Asperen, C J; Rutge 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 124 KB

Tamoxifen and contralateral breast cance

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update

✍ Jacek Gronwald; Nadine Tung; William D. Foulkes; Kenneth Offit; Ruth Gershoni; M 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 77 KB

## Abstract Women with a mutation in __BRCA1__ or __BRCA2__ face a lifetime risk of breast cancer of ∼80%, and following the first diagnosis the10‐year risk of contralateral breast cancer is ∼30%. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is